5,7-二硝基喹恶啉-2,3-二酮 | 125910-83-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5,7-二硝基喹恶啉-2,3-二酮
• 英文名称: 5,7-Dinitroquinoxaline-2,3-dione
• CAS: 125910-83-0
• 化学式: C8H2N4O6
• 分子量: 250.12
• InChiKey: MJMJVOWTLOXTME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  151
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Neuroprotective agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0778023A1

  公开（公告）日：1997-06-11

  This invention provides a method of using rapamycin, rapamycin 1,3-Diels Alder adduct with phenyltriazolinedione, rapamycin 42-ester with 4-[[4-(dimethylamino)phenyl]azo]benzenesulfonic acid, rapamycin 1,3-Diels Alder adduct with methyltriazolinedione, or rapamycin-O-benzyl-27-oxime as a neuroprotective agent.

  本发明提供了一种使用雷帕霉素、雷帕霉素 1,3-Diels Alder 加合物与苯基三唑啉二酮、雷帕霉素 42-酯与 4-[[4-（二甲基氨基）苯基]偶氮]苯磺酸、雷帕霉素 1,3-Diels Alder 加合物与甲基三唑啉二酮或雷帕霉素-O-苄基-27-肟作为神经保护剂的方法。
• SCREENING METHOD
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1788390A1

  公开（公告）日：2007-05-23

  The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of specifically binding to the protein or its salt, which comprises using (a) the protein, its partial peptide, or a salt thereof and (b) the ligand; a screening kit therefor, and so on. The screening method and kit of the present invention are useful for screening an agent for the prevention/treatment of, e.g., digestive tract disorders, cancer, immune disorders, type II diabetes mellitus or obesity, etc.

  本发明提供了一种筛选化合物或其盐的方法，该化合物或其盐可改变包含与 SEQ ID NO: 1 所代表的氨基酸序列相同或基本相同的氨基酸序列的蛋白质或其盐的结合特性，以及能够与该蛋白质或其盐特异性结合的配体，该方法包括使用(a)该蛋白质、其部分肽或其盐和(b)配体；其筛选试剂盒等。本发明的筛选方法和试剂盒可用于筛选预防/治疗消化道疾病、癌症、免疫紊乱、II 型糖尿病或肥胖症等的药物。
• Neuropharmacological treatment of sleep-related breathing disorders
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US20030236228A1

  公开（公告）日：2003-12-25

  The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of glutamate, glycine, or both from nerve terminals with the central nervous system.

  本发明一般涉及通过施用具有谷氨酸相关和/或甘氨酸相关药理活性或调节谷氨酸、甘氨酸或两者从中枢神经系统神经末梢释放的药剂或药剂组合来预防或改善睡眠相关呼吸紊乱的药理方法。
• Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease.
  申请人：Wyeth

  公开号：EP0778023B1

  公开（公告）日：2003-03-12
• Screening Method
  申请人：Ito Yasuaki

  公开号：US20080103215A1

  公开（公告）日：2008-05-01

  The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of specifically binding to the protein or its salt, which comprises using (a) the protein, its partial peptide, or a salt thereof and (b) the ligand; a screening kit therefor, and so on. The screening method and kit of the present invention are useful for screening an agent for the prevention/treatment of, e.g., digestive tract disorders, cancer, immune disorders, type II diabetes mellitus or obesity, etc.